ReviewClinical pharmacokinetics1995
Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.
Review in Clinical pharmacokinetics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 120 citations in OpenAlex.
- Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.Clinical drug investigation · 2013Trial
- Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.Clinical pharmacokinetics · 2006Trial
- Effect of fluoxetine on pharmacokinetics of ritonavir.Antimicrobial agents and chemotherapy · 1998Trial
- Article
- Genome-wide association study reveals a complex genetic architecture underpinning-induced CYP3A4 enzyme activity.European journal of drug metabolism and pharmacokinetics · 2013Article
- Role of cytochrome P450 in drug interactions.Nutrition & metabolism · 2008Article
- The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2007Review
- Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.British journal of clinical pharmacology · 2006Article
- Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.CNS drugs · 2004Review
- Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.British journal of clinical pharmacology · 2000Review
- Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.Clinical pharmacokinetics · 2000Review
- Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.British journal of clinical pharmacology · 1999Article
- Drug interactions of clinical significance with selective serotonin reuptake inhibitors.Drug safety · 1997Review
- Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.Drugs · 1997Review
- Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.Clinical pharmacokinetics · 1997Review
- Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.Clinical pharmacokinetics · 1996Review
- Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?Clinical pharmacokinetics · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Members of the P450 3A subfamily are the most abundant of the human hepatic cytochromes. CYP3A isoforms mediate the biotransformation of many drugs, including a number of psychotropic, cardiac, analgesic, hormonal, immunosuppressant, antineoplastic, and antihistaminic agents. Activity of CYP3A in humans is variable among individuals, but there is no evidence of genetic polymorphism. Significant amounts of CYP3A are present in the gastrointestinal tract, and may contribute to presystemic extraction of drugs such as cyclosporin. The azole antifungal agents ketoconazole and itraconazole are potent inhibitors of human CYP3A isoforms. Selective serotonin reuptake inhibitor (SSRI) antidepressants are also CYP3A inhibitors, but much less potent than ketoconazole or itraconazole. In vitro models can provide important information on the qualitative and quantitative activity of potential inhibitors of human cytochromes. However, in vitro inhibition constant (Ki) values alone do not predict the magnitude of an in vivo interaction, nor whether an interaction will be of clinical importance. For example, SSRIs are predicted to impair clearance of the antihistamine terfenadine in humans. However, the magnitude of this effect is much less than would be associated with a pharmacokinetic interaction of clinical importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.